ArticleTaiwan journal of ophthalmology
Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: A retrospective cohort study.
Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Efficacy of 0.01% atropine for myopia control in children: an artificial intelligence-assisted multivariate Bayesian meta-analysis.Frontiers in medicine · 2026Pooled it
- Myopia progression after cessation of atropine in children: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.Turkish journal of ophthalmology · 2025Article
- Combination Therapy with Atropine 0.05% and Myopi-XTurkish journal of ophthalmology · 2025Article
- Treatment of Rapid Progression of Myopia: Topical Atropine 0.05% and MF60 Contact Lenses.Vision (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the additive potency of low-dose atropine combined with optical measures designed to decrease myopia progression. MATERIALS AND
methodsThis retrospective study included 104 myopic children aged 5-12 over 4 years, divided into five groups: daily instillation of 0.01% atropine and distance single-vision spectacles (A), 0.01% atropine and progressive addition lenses (A + PAL), 0.01% atropine and soft contact lens with peripheral blur (A + CL). Two control groups were included, prescribed bifocal spectacles or single vision (SV) spectacles. Cycloplegic spherical equivalence refraction was measured biannually, including 1 year after cessation of treatment.
resultsA significant decrease in myopia progression was noted during the 2
conclusionAtropine 0.01% presented as effective at decelerating myopia progression, more prominent in the 2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.